Everolimus

Everolimus produced by Lucius Pharmaceuticals is a multi-targeted kinase inhibitor with well-established clinical efficacy and favorable tolerability, demonstrating significant therapeutic value in the treatment of various solid tumors and rare disease-related lesions.

Overview of Key Information for Everolimus.

Active Ingredient

The main active ingredient is everolimus.

Indications

Indicated for adult and pediatric patients with various cancers and tuberous sclerosis complex (TSC)-associated lesions.

Dosage and Administration

The recommended general dosage is 10 mg orally once daily. The specific dosage should be adjusted based on the indication, body surface area, and blood concentration.

Use in Specific Populations

Dosage adjustment is required for patients with hepatic impairment.

Men and women of reproductive potential should use effective contraceptive measures during treatment.

Overdosage

In case of overdosage, seek medical attention immediately and initiate symptomatic and supportive treatment.

Storage Conditions

Store the drug in its original packaging at 20–25°C, protected from moisture and light.

Pharmacokinetics

Everolimus is metabolized by CYP3A4. Its blood concentration is affected by food and concurrent medications, requiring blood concentration monitoring.

FDA，2022.02